

**VIROTECH Borrelia + VlsE IgG Europe ELISA
(Borrelia + VlsE IgG EU ELISA)**

Order-No.: EC024G00 Colour coding: gold/red

Borrelia + VlsE IgG Liquor/CSF Standards

Order-No.: EC022L60

Borrelia + VlsE IgG Liquor/CSF AI Ctrl-Set

Order-No.: EN022L65

Including performance data for CSF diagnosis

FOR IN VITRO DIAGNOSIS ONLY

**VIROTECH Diagnostics GmbH
Löwenplatz 5
D- 65428 Rüsselsheim**

Tel.: +49-6142-6909-0

Fax: +49-6142-6909-19

<http://www.virotechdiagnostics.com>



Contents

1. Intended Use.....	3
2. Diagnostic Relevance.....	3
3. Test Principle.....	4
4. Package Contents.....	4
4.1 Package Contents (IgG Testkit)	4
4.2 Package Contents (IgG CSF-Standards).....	4
5. Storage and Shelflife of the Testkit and the ready to use reagents	5
6. Precautions and Warnings.....	5
7. Material required but not supplied	5
8. Test Procedure – SERUM DIAGNOSTIC	5
8.1 Examination Material.....	5
8.2 Preparation of Reagents	6
8.3 VIROTECH ELISA Test Procedure	6
8.4 Usage of ELISA processors	6
9. Test Evaluation – SERUM DIAGNOSTIC.....	6
9.1 Test function control.....	7
9.2 Calculation of the VIROTECH Units (VE)	7
9.3 Interpretation Scheme IgG	7
9.4 Limits of the Test.....	7
10. Performance Data – SERUM DIAGNOSTIC	8
10.1 Diagnostic Sensitivity	8
10.2 Diagnostic Specificity	8
10.3 Comparison of methods	8
10.4 Cross reactivity	8
10.5 Prevalence (expected values)	9
10.6 Intra-assay coefficient of variation (repeatability).....	9
10.7 Inter-assay coefficient of variation (reproducibility)	9
11. Performance Data CSF-DIAGNOSTIC	10
11.1 Sensitivity and Specificity.....	10
11.2 Cross Reactivity	10
12. References.....	11
13. Test Procedure Scheme	12

1. Intended Use

The B. afzelii+VlsE IgG Europe ELISA serves as screening test for the semiquantitative and qualitative detection of IgG antibodies to *Borrelia burgdorferi* sensu lato in human serum. It can also be used in the parallel testing of paired serum and CSF samples, leading to the quantitative detection of endogenous synthesis of IgG and IgM antibodies.

2. Diagnostic Relevance

Lyme borreliosis (or Lyme disease) is a systemic disease which is caused by infection with the spirochaetes *Borrelia burgdorferi* (1,2). The spirochaetes are transmitted to humans from the bite of an infected tick. In Europe, the tick *Ixodes ricinus* has been identified as the main vector (5). At present, at least three human pathogenic *Borrelia burgdorferi* species are described for Europe (sensu lato), which are summarised under the term *Borrelia burgdorferi* sensu lato: *Borrelia burgdorferi* sensu stricto, *Borrelia garinii* and *Borrelia afzelii* (3,5,6).

Lyme borreliosis is a multisystem disease which develops in stages predominantly affecting the skin, the joints and the nervous system. Because of the wide range of clinical manifestations, the diagnosis of Lyme borreliosis is difficult (5). Among other things, a distinction between the different dermatological diseases (such as B-cell lymphoma of the skin and Lupus erythematosus), neurological diseases (such as multiple sclerosis) and internal diseases (such as arthritis and carditis) (15) is important for differential diagnostics.

The serological diagnostics of Lyme borreliosis is made more difficult by factors such as the following:

- a negative serology, particularly in the early stages, does not rule out Lyme borreliosis. The erythema migrans (primary stage) is seronegative in approximately 50% of cases (14)
- the formation of IgM antibodies can be completely absent
- IgM antibodies can persist over many months (10,11)
- IgG antibodies can still be detected years after clinical remission (10,11)
- cross reactions with other micro organisms have been observed (8,13). Diseases caused by bacteria, such as syphilis and herpes virus infections (particularly EBV), play an important role (12). False positive antibody responses can also occur in the presence of autoimmune antibodies (13).

Lyme borreliosis serology plays a supporting role in clarifying a clinically suspected case. Lyme borreliosis serology can supply important information about seronegativity or confirm a suspected case of fresh infection or advanced infection. However, it is essential that a positive antibody finding be assessed in association with the clinical picture (14).

We recommend carrying out the Lyme borreliosis serology in two stages (16). In the first stage, the samples to be tested should be examined with a sensitive screening test (MiQ12/2000 recommends using an ELISA as a screening test). After this, equivocal and positive sera should be examined in a confirmation test (Line immunoassay/Western Blot). The analysis in the Western Blot enables the antibody response to individual pathogen antigens to be analysed specifically.

The latest development is *in vivo*-expressed antigens and these are also now available for diagnostic use. The special feature of these antigens is that they are only expressed *in vivo* by the borreliae in the infected mammal host (humans). Outstanding among these new *in vivo*-expressed antigens is the general genospecies protein VlsE (17, 18, 19). This acts as a second early marker next to OspC, particularly in IgG serology. Here, the tests have shown that, with early borrelioses, VlsE is frequently found in the IgG as well as the OspC in the IgM and that the sensitivity of the diagnosis of early Lyme borrelioses can be significantly increased.

Neuroborreliosis

In the content of a Borreliosis-infection, symptoms, that concern the nervous system are called Neuroborreliosis. 10 – 15% of patients with Borreliosis develop a Neuroborreliosis. It occurs 5 weeks after the bite of the tick in average. The clinical diagnostic suspicion of patients with Neuroborreliosis can be confirmed by inflammatory CSF-changes and the detection of a borrelia-specific intrathecal antibody-synthesis. The intrathecal specific antibody-production is detected by the determination of the antibody-index. The *B. afzelii* specific intrathecal antibody production is developing in untreated patients during the second week of disease, after three weeks it is detectable in about 75% of the patients and after 8 weeks in more than 99% of the patients. If patients carry the symptoms over a period of more than 2-3 months, a negative Borrelia-antibody test does nearly exclude the possibility of a Neuroborreliosis. The positive detection of only borrelia-specific antibodies does not detect an active

infection with *Borrelia afzelii*. On the other hand the Borrelia Serology might be negative in the early stage of a Borrelia infection – especially at an early treatment with antibiotics (9). During an acute Neuroborreliosis it is eventually possible that the IgG-synthesis might not happen, so that only IgM-antibodies can be found (20).

The antigen used is a mixture of the *B. afzelii* strain PKo (originally isolated from a human erythema migrans lesion in Germany), the *B. garinii* strain PBr (originally isolated from the cerebrospinal fluid of a Neuro Borreliosis patient in Germany), and the *B. burgdorferi* strain ZS7 (originally isolated from an infected tick in Germany) and the *B. burgdorferi* B31 (originally isolated from an infected tick on Shelter Island, N. Y.) recommended for Europe.

Strain	Antigen	Description	Purification	Specificity of the antigens
<i>Borrelia afzelii</i> PKo	Lysate antigen	Bacterial cell lysate, contains all native antigens	Raw cell extract in phosphate buffer	sensitive
<i>Borrelia burgdorferi</i> ZS7	Lysate antigen	Bacterial cell lysate, contains all native antigens	Raw cell extract in phosphate buffer	sensitive
<i>Borrelia garinii</i> PBr	Lysate antigen	Bacterial cell lysate, contains all native antigens	Raw cell extract in phosphate buffer	sensitive
<i>Borrelia burgdorferi</i> B31	VlsE, recombinant	Variable major protein like sequence E. In vivo-expressed lipoprotein, which demonstrates preserved – cross-genospecies – highly immunogenic epitopes. In IgG serology, reactivity to VlsE is observed in the sera of patients with early and with advanced Lyme Borreliosis. In IgG serology, VlsE acts as cross-disease stage Lyme Borreliosis marker. VlsE is a 35 kDa antigen encoded on lp28-1.	Purified from <i>E. coli</i> via Ni-NTA affinity chromatography	specific

3. Test Principle

The antibody searched for in the human serum forms an immune complex with the antigen coated on the microtiter-plate. Unbound immunoglobulins are removed by washing processes. The enzyme conjugate attaches to this complex. Unbound conjugate is again removed by washing processes. After adding the substrate solution (TMB), a blue dye is produced by the bound enzyme (peroxidase). The color changes to yellow when the stopping solution is added.

4. Package Contents

4.1 Package Contents (IgG Testkit)

1. **1 Microtiter-Plate** consisting of 96 with antigen coated, breakable single wells, lyophilised
2. **PBS-Dilution Buffer (blue, ready to use) 2x50ml**, pH 7,2, with preservative and Tween 20
3. **PBS-Washing Solution (20x concentrated) 50ml**, pH 7,2, with preservative and Tween 20
4. **IgG negative Control, 2000µl**, human serum with protein-stabilizer and preservative, ready to use
5. **IgG cut-off Control, 2000µl**, human serum with protein-stabilizer and preservative, ready to use
6. **IgG positive Control, 2000µl**, human serum with protein-stabilizer and preservative, ready to use
7. **IgG-Conjugate (anti-human), 11ml**, (sheep or goat)-horseradish-peroxidase-conjugate with protein-stabilizer and preservative in Tris-Buffer, ready to use
8. **Tetramethylbenzidine substrate solution (3,3',5,5'-TMB), 11ml**, ready to use
9. **Citrate-Stopping Solution, 6ml**, contains an acid mixture

4.2 Package Contents (IgG CSF-Standards)

Borrelia ELISA IgG-Standards for the quantification of pathogen-specific antibody concentrations, 4 vials à 1000µl, human serum with protein-stabilizer and preservative, ready to use, 100wME; 25wME; 6,2wME; 1,5wME (wME = arbitrary measurement units)

5. Storage and Shelflife of the Testkit and the ready to use reagents

Store the testkit at 2-8°C. The shelf life of all components is shown on each respective label; for the kit shelf life please see Quality Control Certificate.

1. Microtiter strips/single wells are to be resealed in package after taking out single wells and stored with desiccant at 2-8°C. Reagents should immediately be returned to storage at 2-8°C after usage.
2. The ready to use conjugate and the TMB-substrate solution are sensitive to light and have to be stored in dark. Should there be a color reaction of the substrate dilution due to incidence of light, it is not useable anymore.
3. Take out only the amount of ready to use conjugate or TMB needed for the test insertion. Additional conjugate or TMB taken out may not be returned but must be dismissed.

Material	Status	Storage	Shelflife
Test Samples	Diluted	+2 to +8°C	max. 6h
	Undiluted	+2 to +8°C	1 week
Controls	After Opening	+2 to +8°C	3 months
Microtitreplate	After Opening	+2 to +8° (storage in the provided bag with desiccant bag)	3 months
Rheumatoid factor - Absorbent	Undiluted, After Opening	+2 to +8°C	3 months
	Diluted	+2 to +8°C	1 week
Conjugate	After Opening	+2 to +8°C (protect from light)	3 months
Tetramethylbenzidine	After Opening	+2 to +8°C (protect from light)	3 months
Stop Solution	After Opening	+2 to +8°C	3 months
Washing Solution	After Opening	+2 to +8°C	3 months
	Final Dilution (ready-to-use)	+2 to +25°C	4 weeks

6. Precautions and Warnings

1. Only sera which have been tested and found to be negative for HIV-1 antibodies, HIV-2 antibodies, HCV antibodies and Hepatitis-B surface-antigen are used as control sera. Nevertheless, samples, diluted samples, controls, conjugates and microtiter strips should be treated as potentially infectious material. Please handle products in accordance with laboratory directions.
2. Those components that contain preservatives, the Citrate Stopping Solution and the TMB have an irritating effect to skin, eyes and mucous. If body parts are contacted, immediately wash them under flowing water and possibly consult a doctor.
3. The disposal of the used materials has to be done according to the country-specific guidelines.

7. Material required but not supplied

1. Aqua dest./demin.
2. Eight-channel pipette 50µl, 100µl
3. Micropipettes: 10µl, 100µl, 1000µl
4. Test tubes
5. Paper towels or absorbent paper
6. Cover for ELISA-plates
7. Disposal box for infectious material
8. ELISA handwasher or automated EIA plate washing device
9. ELISA plate spectrophotometer, wavelength = 450nm, reference length = 620nm (Reference Wavelength 620-690nm)
10. Incubator

8. Test Procedure – SERUM DIAGNOSTIC

Working exactly referring to the VIROTECH Diagnostics user manual is the prerequisite for obtaining correct results.

8.1 Examination Material

Either serum or plasma can be used as test material, even if only serum is mentioned in the instructions. Any type of anticoagulant can be used for plasma.

Always prepare patient-dilution freshly.

For a longer storage the sera must be frozen. Repeated defrosting should be avoided.

1. Only fresh non-inactivated sera should be used.
2. Hyperlipaemic, haemolytic, microbially contaminated and turbid sera should not to be used (false positive/negative results).

8.2 Preparation of Reagents

The VIROTECH Diagnostics System Diagnostica offers a high degree of flexibility regarding the possibility to use the dilution buffer, washing solution, TMB, citrate stopping solution as well as the conjugate for all parameters and for all different lots. The ready to use controls (positive control, negative control, cut-off control) are parameter specific and only to use with the plate lot indicated in the Quality Control Certificate.

1. Set incubator to 37°C and check proper temperature setting before start of incubation.
2. Bring all reagents to room temperature before opening package of microtiter strips.
3. Shake all liquid components well before use.
4. Make up the washing solution concentrate to 1 L with distilled or demineralised water. If crystals have formed in the concentrate, please bring the concentrate to room temperature before use and shake well before use.

8.3 VIROTECH ELISA Test Procedure

1. For each test run, pipette 100µl each of ready to use dilution buffer (blank), IgG-positive, negative and cut-off control as well as diluted patient sera. We propose a double insertion (blank, controls and patient sera); for cut-off control a double insertion is absolutely necessary. Working dilution of patient sera: 1+100; e.g. 10µl serum + 1ml dilution buffer.
2. After pipetting start incubation for 30 min. at 37°C (with cover).
3. End incubation period by washing microtiter strips 4 times with 350 – 400µl washing solution per well. Do not leave any washing solution in the wells. Remove residues on a cellulose pad.
4. Pipette 100µl of ready to use conjugate into each well.
5. Incubation of conjugates: 30 min. at 37°C (with cover).
6. Stop conjugate incubation by washing 4 times (pls. refer to point 3 above).
7. Pipette 100µl of ready to use TMB into each well.
8. Incubation of substrate solution: 30 min. at 37°C (with cover, keep in dark).
9. Stopping of substrate reaction: pipette 50µl of citrate stopping solution into each well. Shake plate carefully and thoroughly until liquid is completely mixed and a homogeneous yellow color is visible.
10. Measure extinction (OD) at 450/620nm (Reference Wavelength 620-690nm). Set your photometer in such a way that the blank value is deducted from all other extinctions. Extinctions should be measured within 1 hour after adding the stopping solution!

Pls. refer to last page for Test Procedure Scheme

8.4 Usage of ELISA processors

All VIROTECH Diagnostics ELISAs can be used on ELISA processors. The user is bound to proceed a validation of the devices (processors) on a regular basis.

VIROTECH Diagnostics recommends the following procedure:

1. VIROTECH Diagnostics recommends to proceed the validation of device referring to the instructions of the device manufacturer during the implementation of the ELISA processor respectively after bigger reparations.
2. It is recommended to check the ELISA-processor with the Validationkit (EC250.00) afterwards. A regular check using the Validationkit shall be proceeded minimum once a quarter to test the accuracy of the processor.
3. The release criteria of the Quality Control Certificate of the product must be fulfilled for each testrun.

With this procedure, your ELISA processor will function properly, and this will support quality assurance in your laboratory.

9. Test Evaluation – SERUM DIAGNOSTIC

The ready to use controls serve for a semiquantitative determination of specific IgG antibodies. Their concentration can be expressed in VIROTECH units = VE. Fluctuations resulting from the test procedure can be balanced with this calculation method and a high reproducibility is achieved in this way. Use the means of the OD values for calculation of the VE.

9.1 Test function control

a) OD-values

The OD of the blank should be < 0.15.

The OD-values of the negative controls should be lower than the OD-values mentioned in the Quality Control Certificate. The OD-values of the positive controls as well as of the cut-off controls should be above the OD-values mentioned in the Quality Control Certificate.

b) VIROTECH Units (VE)

The VIROTECH Units (VE) of the cut-off controls are defined as 10 VE. The calculated VE of the positive controls should be within the ranges mentioned in the Quality Control Certificate.

If those requirements (OD-values, VE) are not fulfilled, the test has to be repeated.

9.2 Calculation of the VIROTECH Units (VE)

The extinction of the blank value (450/620nm) has to be subtracted from all other extinctions.

$$\begin{aligned} \text{VE (positive control)} &= \frac{\text{OD (positive control)}}{\text{OD (cut-off control)}} \times 10 \\ \text{VE (patient serum)} &= \frac{\text{OD (patient serum)}}{\text{OD (cut-off control)}} \times 10 \end{aligned}$$

9.3 Interpretation Scheme IgG

Result (VE)	Evaluation
< 9,0	negative
9,0 - 11,0	borderline
> 11,0	positive

1. If the measured values are above the defined borderline range, they are considered to be positive.
2. If the measured VE is within the borderline range, no significant high antibody concentration is present, the samples are considered to be borderline. For the secure detection of an infection it is necessary to determine the antibody concentration of two serum samples. One sample shall be taken directly at the beginning of the infection and a second sample 5 – 10 days later (convalescent serum). The antibody concentration of both samples has to be tested in parallel, that means in one test run. A correct diagnosis based on the evaluation of a single serum sample is not possible.
3. If the measured values are below the defined borderline range, no measurable antigen specific antibodies are present in the samples. The samples are considered to be negative.

9.4 Limits of the Test

1. The interpretation of serological results shall always include the clinical picture, epidemiological data and all further available laboratory results.
2. The cross-reaction between *Borrelia* and other spirochaeta may lead to a false positive result. Sera of patients with the following infections may cross-react: Syphilis (*Treponema pallidum*), Framboesia (*Treponema pertenue*), Recurrent Fever (*Borrelia spec.*), Leptospirosis (*Leptospira spec.*). Furthermore there may occur cross-reactions with Herpes Diseases (CMV, HSV, Parvovirus) (12, 13).
3. During an EBV infection (infectious mononucleosis), the non-specific formation of anti-borrelia antibodies, particularly of the IgM class, may occur (12, 13).

10. Performance Data – SERUM DIAGNOSTIC

10.1 Diagnostic Sensitivity

To determine the Diagnostic Sensitivity, a total of 79 clinically characterised samples from patients with Lyme disease Early Manifestations (n=36), with neuroborreliosis (n=11), with Lyme arthritis (n=12) and with ACA (n=20) were tested on the VIROTECH Borrelia + VlsE IgG Europe ELISA. Diagnostic Sensitivity was determined separately for each clinical phase. Borderline samples (n=3) were not considered in the calculation of Diagnostic Sensitivity.

Diagnostic Sensitivity Early Manifestation	negative	borderline	positive	Sensitivity [%]
	12	2	22	64,7

Diagnostic Sensitivity ACA	negative	borderline	positive	Sensitivity [%]
	0	0	20	100

Diagnostic Sensitivity Lyme Arthritis	negative	borderline	positive	Sensitivity [%]
	0	0	12	100

Diagnostic Sensitivity Neuroborreliosis	negative	borderline	positive	Sensitivity [%]
	1	1	9	90,0

10.2 Diagnostic Specificity

To determine the Diagnostic Specificity, a total of 93 samples from healthy blood donors in Germany were tested with a reference ELISA. The samples that were negative on the reference test were subsequently tested on the VIROTECH Borrelia + VlsE IgG Europe ELISA. The Diagnostic Specificity was determined. Borderline samples (n=2) were not considered in the calculation of the Diagnostic Specificity.

Diagnostic Specificity	negative	borderline	positive	Specificity [%]
	87	2	4	95,6

10.3 Comparison of methods

To determine sensitivity and specificity, positive, clinically characterised samples from patients with Lyme borreliosis (n=79) and samples from healthy blood donors from Germany (n=101) were tested in the VIROTECH Borrelia + VlsE IgG Europe ELISA and with a reference ELISA.

Sample collective (n=180)		reference ELISA		
		negative	borderline	positive
VIROTECH Borrelia + VlsE IgG Europe ELISA	negative	94	5	3
	borderline	4	0	2
	positive	8	3	61

The borderline samples were not considered in the calculation of sensitivity and specificity.

This results in a sensitivity of 95% for the VIROTECH Borrelia + VlsE IgG Europe ELISA.

This results in a specificity of 92% for the VIROTECH Borrelia + VlsE IgG Europe ELISA.

10.4 Cross reactivity

Cross reactions are known with Treponema-positive sera.

Borrelia reactive sera can be produced during infection associated with Herpes virus infections (predominantly with EBV).

Cross-reactions with mycoplasma, Helicobacter pylori, CMV, Parvo and Yersinia sera as well as autoimmune sera are less common.

Treponema pallidum positive sera, EBV positive sera as well as autoimmune sera were investigated on the VIROTECH Diagnostics Borrelia + VIsE IgG Europe ELISA with regard to their cross-reactivity:

Collective	pos	neg	borderline	Sum
<i>Treponema pallidum</i> pos. sera	4	8	10	22
EBV pos. sera	0	9	1	10
Autoimmune sera	1	14	0	15

10.5 Prevalence (expected values)

A panel of 101 samples from healthy blood donors in Germany was tested with the VIROTECH Borrelia + VIsE IgG Europe ELISA.

VIROTECH Borrelia + VIsE IgG Europe ELISA	negative	borderline	positive
Sample collective (n=101)	89	3	9

This results in a prevalence of 8.9%.

In the literature, a prevalence of 4-15% has been described in the period 1989-2012. (23)

10.6 Intra-assay coefficient of variation (repeatability)

In one assay, the strips of different plates from one lot were tested with a serum. The coefficient of variation determined was < 9%.

10.7 Inter-assay coefficient of variation (reproducibility)

In 10 independent test runs, 3 serum were tested in different laboratories by different test persons. The coefficient of variation determined was < 9%.

11. Performance Data CSF-DIAGNOSTIC

Proof of a specific intrathecal antibody production based on the antibody index determination according to Reiber (21)

11.1 Sensitivity and Specificity

For the detection of the **diagnostic** sensitivity, defined Neuroborreliosis-positive CSF/Serum-pairs have been tested using the VIROTECH ELISA.

Diagnostic Sensitivity IgG

	n	%
total	26	100
pathological	26	100
normal	0	0

The sensitivity is > 99,9%. It therefore fits to the range for sensitivity of the antibody detection procedures in the Lyme-Borreliosis-Diagnostic stage II / III (70-100%) mentioned in the MIQ.

For the detection of the **diagnostic** specificity, defined CNS-negative CSF-serum pairs have been tested using the VIROTECH ELISA.

Diagnostic Specificity IgG

	n	%
total	19	100
pathological	0	0
normal	19	100

The specificity is > 99,9% for IgG.

For the detection of the sensitivity and specificity, CSF-serum-pairs of ensured Neuroborreliosis, CSF-serum-pairs with suspicion of Neuroborreliosis samples have been tested using the VIROTECH Borrelia + VlsE IgG ELISA with IgG CSF-Standards and a reference-test.

Sensitivity and Specificity IgG

CSF/serum-pairs (n=59)

VIROTECH ELISA	reference-test	
	pathological	normal
pathological	26	3
normal	0	30

In IgG the sensitivity for CSF with the VIROTECH Borrelia +VlsE IgG ELISA is > 99,9% and the specificity is 90,6%.

11.2 Cross Reactivity

The same antibodies are present in the cerebrospinal fluid and the serum (22). As a consequence, cross-reactions with antibodies against the same pathogens can occur in serological diagnostics as well as in cerebrospinal fluid diagnostics. For this reason, the data from serology can be applied to cerebrospinal fluid diagnostics.

12. References

1. Burgdorfer, W., Barbour, A.G., Hayes S.F. et al. (1982), Lyme disease - a tick -borne spirochetosis?, *Science* 216:1317-19.
2. Steere, A.C. (1989), Lyme Disease, *N. Engl. J. Med.* 321:586-96.
3. Dressler, F., Ackermann, R. and Steere, A.C. (1994), Antibody responses to the three genomic groups of *Borrelia burgdorferi* in European Lyme Borreliosis, *J. Infect. Dis.* 169: 313-318.
4. Hofmann, H. (1996) Lyme Borreliosis – Problems of Serological Diagnosis, *Infection* 24, No. 6 :470-472.
5. Pfister, H-W., Wilske, B. (1994) Lyme borreliosis: basic science and clinical aspects, *The Lancet* Vol. 343: 1013-1015.
6. Dressler, F. (1994) Lyme borreliosis in European children and adolescents, *Clinical and Experimental Rheumatology* 12 (Suppl. 10) :49-54.
7. Hansen, K. (1993), Laboratory Diagnostic Methods in Lyme Borreliosis, Elsevier Science Publishing Co., Inc.:12.
8. Tewald, F. Braun, R. (1998), Durchführung und Interpretation serologischer Tests bei Verdacht auf Borrelieninfektion [*Procedure and Interpretation of Serological Tests for suspected Borreliosis Infection*], *Clin. Lab.* 44: 897-902.
9. Goosens, H.A.T., Bogaard, van den A.E., Nohlmans, M.K.E., (1999), Evaluation of Fifteen commercially available serological tests for diagnosis of Lyme borreliosis, *Eur. J. Microbiol. Infect. Dis* 18: 551-560.
10. Craft, J.E., Fischer, D.K., Shimamoto, G.T. and Steere, A.C. (1986), Antigens of *Borrelia burgdorferi* recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G late in the illness., *J. Clin. Invest.* 78:934-39.
11. Craft, J.E., Grodzicki, R.L. and Steere, A.C. (1984), Antibody response in Lyme disease: evaluation of diagnostic tests, *J. Inf. Dis.* 149:789-95.
12. Goosens, H.A.T., Bogaard, van den A.E., Nohlmans, M.K.E., (1999), Epstein-Barr Virus and Cytomegalovirus Infections cause false positive results in IgM two-test protocol for early Lyme-Borreliosis, *Infection* 27 No.3: 231.
13. Horst, H. (1997), Einheimische Zeckenborreliose (Lyme-Krankheit) bei Mensch und Tier [*Endemic Tick Borreliosis (Lyme disease) in Humans and Animals*], 3., überarbeitete Auflage, Spitta Verlag: 128-130.
14. RKI (1999), Ratgeber Infektionskrankheiten, Lyme-Borreliose [*Encyclopaedia of Infectious Diseases, Lyme Borreliosis*], Epidemiologisches Bulletin, überarbeitete Auflage
15. Oschmann und Kraiczy (1998) Lyme-Borreliose und Frühsommer-Meningoenzephalitis [*Lyme Borreliosis and Spring-Summer Meningo Encephalitis*], UNI-MED-Verlag 48-67.
16. Wilske et al. MiQ12/2000; Urban&Fischer
17. Zhang, J-R. et al.; Antigenic variation in Lyme disease *Borrelia* by promiscuous recombination of VMP-like sequence cassettes; *Cell* 1997. 89:275-285
18. Lawrenz, M.B. et al.; Human antibody responses to VlsE antigenic variation protein of *Borrelia burgdorferi*; *American Society of Clinical Microbiology*; Dec. 1999: 3997-4004.
19. Wang, D., Botkin, D.J. and Norris, S.J.; Characterization of the vls antigenic variation loci of the Lyme disease spirochaetes *Borrelia garinii* Ip90 and *Borrelia afzelii* ACAI (2003); *Molecular Microbiology*; 47(5): 1407-1417.
20. Felgenhauer K, Beuche W: Labordiagnostik neurologischer Erkrankungen; Thieme Verlag, Stuttgart, New York, 1999
21. Reiber H., und Lange P. (1991) Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain, *Clin Chem* 37: 1153-60
22. Reiber, H. und Peter J. B. (2001) Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs, *Journal of the Neurological Sciences* 184: 101-122.
23. [Estimates for Lyme borreliosis infections based on models using sentinel canine and human seroprevalence data. M.J. Cook and B.K. Puri \(2020\). Infectious Disease Modelling 5 \(2020\) 871-888. <https://doi.org/10.1016/j.idm.2020.10.004>.](#)

Preparation of Patient Samples and Washing Solution

▼ **Washing Solution:** Fill up concentrate to 1 liter with aqua dest./demin.

IgG-Samples – Dilution 1:101

e.g.:

10 µl serum/plasma + 1000 µl Dilution Buffer
(Serum Dilution Buffer is ready to use)

Testprocedure

